<DOC>
	<DOCNO>NCT00514917</DOCNO>
	<brief_summary>The primary objective evaluate compare efficacy androgen deprivation without docetaxel determine median progression free survival ( PFS ) period 18-month therapy least 18-month follow-up . The secondary objective : - To assess cancer specific survival ; - To compare overall survival 2 treatment group ; - To evaluate patient-reported outcome include quality life , fatigue , sexual functioning measure 3 different assessment .</brief_summary>
	<brief_title>A Study Androgen Deprivation With Leuprolide , +/- Docetaxel Clinically Asymptomatic Prostate Cancer Participants With Rising Prostate Specific Antigen ( PSA )</brief_title>
	<detailed_description>The duration study per participant least 36 month , treatment period 18 month participant , follow least 18 month follow-up period . Participants receive study treatment 18 month time study therapy initiation le one following occur : disease progression , unacceptable toxicity , death , participant refusal treatment delay beyond time frame permit treatment .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Diagnosis prostate adenocarcinoma pathologically confirm History radical prostatectomy ( preoperative radiation therapy prostate pelvis salvage radiation radical prostatectomy allow ) Demonstration biochemical progression disease base prostate specific antigen ( PSA ) double time . The minimum PSA value eligibility great equal ( &gt; = ) 1 . PSA double time three value must equal ( = ) 9 month minimum 3 week assessment Serum testosterone &gt; =100 nanogram per deciliter ( ng/dL ) Karnofsky performance status ( KPS ) &gt; =70 percent ( % ) Adequate organ function define follow laboratory criterion : White blood cell &gt; =3500 per cubic millimeter ( mm^3 ) Absolute neutrophil count ( ANC ) &gt; =1500 per mm^3 Platelet count &gt; =100,000 per mm^3 Hemoglobin &gt; = 10.0 gram per deciliter ( g/dL ) Total Bilirubin less equal ( &lt; = ) upper limit normal ( ULN ) unless due Gilbert 's disease Creatinine l &lt; = 1.5 milligram per deciliter ( mg/dL ) creatinine clearance &gt; =60 cubic centimeter per minute Aspartate transaminase ( AST ) , alanine transaminase ( ALT ) alkaline phosphatase within predefined range Previous hormonal therapy allow provided total duration therapy exceed 6 month Man childbearing potential willing consent use effective contraception treatment least 3 month thereafter Participant willing able comply schedule visit , treatment plan , laboratory test , study procedure Clinically significant cardiac disease ( New York Heart Association Class III/IV ) , severe debilitate pulmonary disease Uncontrolled serious active infection Anticipated duration life &lt; 2 year Less 5year history successful treatment cancer concurrent active nonprostate cancer nonmelanoma dermatologic tumor Peripheral neuropathy &gt; =Grade 2 History hypersensitivity reaction Docetaxel drug formulate polysorbate 80 , leuprolide , bicalutamide Prior chemotherapy within past 10 year ( except nontaxane base chemotherapy treatment cancer ) ; concurrent treatment another clinical trial cancer therapy include chemotherapy , immunotherapy , radiotherapy ( except salvage radiation therapy ) , chemoembolization therapy , cryotherapy Other severe acute chronic medical condition include psychiatric disease , significant laboratory abnormality require investigation may cause undue risk participant 's safety , delay prohibit protocol participation , interfere interpretation study result , judgment investigator would make participant inappropriate entry study Radiographic finding suspicious metastatic disease treat physician 's clinical judgment . Participant radiographically suspicious pelvic lymph node prior radial prostatectomy , , time enrollment suspicious adenopathy eligible . Participant eligible even he/she tumorcontaining pelvic adenopathy time surgery long time enrollment radiographically evident nodal disease clinician 's opinion Participant investigator subinvestigator , research assistant , pharmacist , study coordinator , staff relative thereof directly involve conduct protocol Participant unlikely comply protocol research test , example , uncooperative attitude , inability return followup visit , unlikelihood complete study Participant participate another clinical study/received investigational product within 30 day screen The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>